Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919939 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
A Phase 2 study of Large B-cell Lymphoma and Relapse, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT06919939 is a Phase 2 study of Large B-cell Lymphoma and Relapse that is actively recruiting participants, run by University of Miami. The registered enrollment target is 26 participants, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06919939, a Phase 2 study of Large B-cell Lymphoma and Relapse, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
Conditions Studied
Interventions
- DRUG Epcoritamab
- DRUG Loncastuximab Tesirine
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2031-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06919939
The ClinicalTrials.gov registry entry for NCT06919939 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (84% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Epcoritamab is the first listed.
NCT06919939 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06919939 about?
NCT06919939 is a clinical study titled "Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma". The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
What is the current status of trial NCT06919939?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2026-01-07. Estimated completion is 2031-01-07.
What conditions does trial NCT06919939 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma, Relapse.
What interventions are being tested in trial NCT06919939?
The interventions under investigation include: Epcoritamab (DRUG), Loncastuximab Tesirine (DRUG).
Who is sponsoring clinical trial NCT06919939?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06919939 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.